Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for obsessive-compulsive disorder
IRCT20210310050660N1Phase 3Completed
- Sponsor
- Qazvin University of Medical Sciences
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in obsessive compulsive disorder (OCD) comparing Cannabidiol plus standard treatment with Placebo plus standard treatment (2 arms). Primary endpoints: Yale-Brown Obsessive Compulsive Scale score at week 8 and Obsessive-Compulsive Scale at week 8. Started Apr 2021; status: completed.
02
Drugs
cannabidiol
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on IRCT20210310050660N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210310050660N1.